Repro Med Systems Inc
NASDAQ:KRMD
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Repro Med Systems Inc
NASDAQ:KRMD
|
US |
|
Cool Technologies Inc
OTC:WARM
|
US |
Repro Med Systems Inc
Repro-Med Systems, Inc. engages in the design, manufacture, and market of proprietary medical devices. The company is headquartered in Chester New York, New York and currently employs 77 full-time employees. The company is focused on the developing, manufacturing, and commercializing of specialty infusion solutions. The firm's products include the FREEDOM Infusion Systems, which consist of the FREEDOM60 Syringe Driver, the FreedomEdge Syringe Driver, HIgHFlo Subcutaneous Safety Needle Sets and Precision Flow Rate Tubing. The FREEDOM System operates at a lower pressure and maintains a balance between what a patient’s subcutaneous tissues can absorb and what the system delivers. The firm performs product assembly, calibration, pre- and post-assembly quality control inspection and testing, and final packaging for all its products at its Chester, New York facility.
Repro-Med Systems, Inc. engages in the design, manufacture, and market of proprietary medical devices. The company is headquartered in Chester New York, New York and currently employs 77 full-time employees. The company is focused on the developing, manufacturing, and commercializing of specialty infusion solutions. The firm's products include the FREEDOM Infusion Systems, which consist of the FREEDOM60 Syringe Driver, the FreedomEdge Syringe Driver, HIgHFlo Subcutaneous Safety Needle Sets and Precision Flow Rate Tubing. The FREEDOM System operates at a lower pressure and maintains a balance between what a patient’s subcutaneous tissues can absorb and what the system delivers. The firm performs product assembly, calibration, pre- and post-assembly quality control inspection and testing, and final packaging for all its products at its Chester, New York facility.
Leadership: CEO Linda Tharby will retire effective June 30; CCO Adam Kalbermatten is named successor (President March 15, CEO July 1).
Revenue: Q4 revenue was $10.9 million (up 23% YoY); full-year 2025 revenue was $41.1 million (up 22% YoY).
Guidance: 2026 revenue guidance of $47.5 million to $50.0 million (growth of 15% to 22%) with positive adjusted EBITDA and positive cash flow for the full year.
Margins & profit: Full-year gross margin was 62.3%; company delivered positive adjusted EBITDA of $600,000 for 2025 and expects 2026 gross margins of 61%–63%.
Patient & pipeline scale: Recurring base of ~59,000 global chronic SCIg patients; 9 drugs cleared on the FREEDOM system and 9 active development opportunities with partners.
International momentum: International Core grew 71% in Q4 and 80% for the year, driven by prefilled syringe conversions; Europe addressable market cited at ~$50 million.
Cash & cash flow: Year-end cash of $8.9 million, full-year cash usage of $700,000, and positive operating cash flow in Q3, Q4 and for the full year.
